Globeflex Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Globeflex Capital’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-105	Closed	-$1K	–	582
2016 Q1	$1K	Buy	+105	New	+$839	﹤0.01%	435
2015 Q3	–	Sell	-12,000	Closed	-$234K	–	635
2015 Q2	$234K	Buy	12,000 +8,182	+214%	+$158K	0.04%	371
2015 Q1	$69K	Buy	+3,818	New	+$85.9K	0.01%	379

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Globeflex Capital's CTIC Position: Q2 2016 in Review

Globeflex Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2016, closing a stake of 105 shares — an estimated $1K sold.

Globeflex Capital first reported a position in CTIC in Q1 2015 and held it in 3 quarters. The position peaked at $234K in Q2 2015. 67 funds tracked by Wall St. Rank hold CTIC as of Q2 2016.

Globeflex Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2016 after selling out during the quarter.
Globeflex Capital sold 105 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2016, an estimated $1K.
Globeflex Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2015 and held it in 3 quarters.
Globeflex Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $234K in Q2 2015.
67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2016.

Based on Globeflex Capital's 13F filing for Q2 2016, filed 10 Aug 2016.